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Abstract 
 Patients with neuromuscular disease (NMD) requiring tracheostomy and mechanical 
ventilation secondary to respiratory failure encounter increased difficulty in removing pulmonary 
secretions from the airways. To combat issues associated with current treatment modalities for 
insufficient cough efficacy (cost, poor mobility, discomfort, lack of evidence), we have 
developed an instrumentational proximal airway clearance technique (ACT) which augments a 
manual proximal ACT developed by a client with NMD. QuickCough is a 3D-printed PLA 
attachment to the tracheostomy apparatus which has demonstrated its ability to facilitate pressure 
changes necessary to increase patient’s peak cough flow (PCF) by providing a stronger 
exsufflation for the patient. QuickCough meets client needs by providing a machine-washable, 
inexpensive method of facilitating secretion expulsion without the use of bulky equipment in-
transit. This novel instrumentational augmentation of a manual ACT was designed using the 
engineering design process discussed in The University of Akron’s biomedical engineering 
design course 4800:470. Future work ought to focus on development of an automated procedure 
to allow application of QuickCough in cases of global paralysis or insufficient home-care.  
Description of the Project Problem 
Patients who are no longer able to carry out normal respiration may require respiratory 
support with the use of a tracheostomy [1], which is a surgical procedure performed to bypass 
the upper airway and create access to apply ventilatory respiratory support [2]. A modified 
endotracheal tube is then inserted through the tracheostomy to maintain the airway indefinitely 
(Figure 1a). A small balloon at the distal end of the tracheostomy tube (TOT) is inflated with 
saline to maintain a sufficient seal and prevent aspiration (Figure 1b). Tracheostomy is 
accompanied by mechanical ventilation through the tracheostomy apparatus by an external 
pump,  
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Figure 1. (a) Image of a tracheostomy tube being passed through the tracheostomy incision of canine model 
(https://ccforum.biomedcentral.com/articles/10.1186/cc4926). (b) Illustration of implanted tracheostomy tube, highlighting location of exterior 
port and presence of saline-inflated balloon distally (https://www.mayoclinic.org/tests-procedures/tracheostomy/about/pac-20384673). 
 
which facilitates the respiratory cycle and maintains homeostatic gas exchange [3]. Illustrations 
of these devices are shown in Figure 2. Short-term utilization of tracheostomy for mechanical 
ventilation may be indicated in young or healthy patients who have undergone acute trauma, 
extensive surgery, or have a tortuous upper airway preventing traditional endotracheal intubation 
(see Figure 2) [4-6]. The most common indication for long-term mechanical ventilation is acute 
respiratory failure [7], which may be caused by infection, major adverse cardiovascular events, 
worsening of chronic respiratory disease, acute asthma, trauma, neuromuscular disease (NMD), 
or a combination of these [8, 9]. Tracheostomy is currently the best modality for long-term 
mechanical ventilation, as traditional endotracheal intubation poses a number of threats to the 
patient in long-term use [10, 11]. Despite the benefits of tracheostomy in long-term management 
of respiratory failure, there are several significant adverse events which may occur in patients 
with tracheostomy, which are reviewed in depth by Stauffer et al [11]. The scope of this project 
pertains to patients with acute respiratory failure secondary to neuromuscular disease, and the 
subsequent inability to expel secretions from the respiratory tract; therefore, please refer to the 
aforementioned review [11] for additional information. 
 
 
Figure 2. (a) Tracheostomy tube with components. Note the saline-inflated balloon at the distal end of the device, as well as two sleeve 
components for surgical placement (https://www.hopkinsmedicine.org/tracheostomy/about/types.html). (b) Mechanical ventilation machine. A 
device such as this is typically found in the home of mechanically-ventilated patients (https://www.sonashomehealth.com/medical-ventilator/). (c) 
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Traditional endotracheal intubation. Note the passage of the artificial airway through the vocal cords as opposed to a surgical incision through the 
anterior neck. In a tortuous airway, passing the endotracheal tube may be harmful or impossible (https://emedicine.medscape.com/article/109739-
overview). 
 
Patients with NMD are at increased risk of respiratory-related mortality due to 
diminishing gas exchange and inability to remove airway secretions [12]. Tussis, or coughing, is 
a mechanism by which airway secretions are expelled to prevent infection, acidosis, hypoxia, 
atelectasis, or obstruction [13]. In conjunction with progressive neuromuscular pathology, 
undergoing TOT placement presents anatomical and physiologic changes which may disturb or 
burden the cough cycle. In the setting of progressive neuromuscular disorder, patients may have 
weakened inspiratory and expiratory muscle groups preventing large-volume exsufflation 
required to expel pulmonary secretions [13-15]. Secretion burden is exacerbated by placement of 
a TOT, which causes excess tracheal secretion build-up in and around the TOT despite 
traditional preventative measures such as suction or humidification [16-20]. Complications 
related to secretion build-up include TOT blockage and life-threatening infection caused by 
retained microorganisms [16, 21-24].  
Many techniques are available to augment the coughing mechanism for NMD patients 
who are mechanically ventilated through tracheostomy (NMDmvT), which are well-reviewed by 
Chatwin et al [25]. Briefly, assisted cough techniques (ACTs) may be designated into two 
categories. Proximal ACTs directly impact the patient’s peak cough flow (PCF) by aiding in 
inspiratory or expiratory pressures. The scope of this project centralizes around adverse events 
associated with the use of a mechanical insufflation-exsufflation (MI-E) device, which aims to 
replicate the airflow seen in a normal cough by augmenting inspiration with positive-pressure, 
followed rapidly by negative-pressure to force the air out of the lungs. This modality is 
commonly indicated in NMDmvT patients, who have poor inspiratory and expiratory 
performance [25-27]. These devices are unable to provide mobile care given their size and are 
often limited to the confines of a home or hospital suite. Complications of this technique are 
uncommon but significant [28, 29], the most immediate concern being thoracic wall discomfort 
and anxiety with loss-of-control of the respiratory cycle [13]. Additionally, MI-E devices are 
costly, and may not be reimbursed or available in certain regions [25, 26].  
Peripheral ACTs indirectly improve cough efficacy by loosening and mobilizing 
secretions from small airway structures into large airways, which allows for more clearance 
during cough cycles [30]. The two peripheral ACTs contested in the scope of this project are the 
use of a high frequency chest wall oscillation (HFCWO) vest, and development of a manual 
technique to loosen secretions. These items will be further described in the background section 
of this report. Instrumentation for peripheral ACTs are limited by high cost, routine need for 
subsequent use of a proximal ACT, and risk of respiratory arrest secondary to sudden 
mobilization of large-volume secretions into major airways [25, 31, 32]. Pitfalls of manual 
peripheral ACTs include insufficient evidence-based medicine directing their use in NMD and 
poor understanding of physiologic effects [25]. Particularly in moderate-to-severe NMD, a 
limitation of all present ACTs is the need for a caretaker to assist with or perform the technique.  
In light of the current modalities and limitations of airway clearance in patients with 
NMD, a clear subset of NMDmvT patients are identified as underequipped for management of 
airway secretions. Many NMDmvT patients may still be attending school, even at the collegiate 
level, and require the resources to perform adequate airway clearance outside of their primary 
care center or home. Many of these patients use instrumentational or manual peripheral ACTs in 
conjunction with suctioning, but as previously discussed, is not as effective as techniques such as 
MI-E [25, 26, 33, 34]. Patients who note anxiety or discomfort with more invasive modalities 
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also ought to have a sufficient manual technique which provides them with the sense of control 
and security needed to maintain cooperativity and effectiveness of treatment. Throughout the 
course of this project, we aimed to develop a solution which addresses the main problems 
addressed throughout this section, as well as additional well-known concerns: cost, portability, 
ease-of-use, sterility, and production of adequate pressure waveform to generate effective airway 
clearance. The scope of this project centers around mild-to-moderate cases of NMD in which 
patients have some independence of respiratory-related muscle groups. Prognostically, NMD 
patient conditions will continue to progressively worsen and require more aggressive 
management of respiratory failure throughout disease development [35]. 
Background 
 The client for this project is a 22-year-old male with progressive NMD who, for the past 
7 years, has required mechanical ventilation through his tracheostomy tube secondary to NMD-
associated respiratory failure. Secondary to global neuromuscular decomposition, he depends on 
mobility through use of a motorized chair, as well as direct care with the help of a family 
caretaker. Despite his disabilities, the client is an active student at a nearby university, attending 
classes regularly and involved in extracurricular activities. He follows up for respiratory care at a 
nearby pediatric tertiary care center, where he has received his care since notable onset of NMD-
related symptoms and respiratory insufficiency. The client’s respiratory management over the 
past several years has been widely variable, and significant complications of his disease have 
included numerous admissions over the past several years related to secretion burden in the 
central airways. At home, he uses a currently marketed MI-E device for proximal airway 
clearance, as well as a HFCWO vest for peripheral support; however, the MI-E device is 
associated with thoracic wall discomfort and emotional stress and during use, forces his caretaker 
to disconnect his ventilation tube, and decreases his mobility while transitioning from home to 
school. Unfortunately, the utilization of multiple instrumentational techniques has not eliminated 
pneumonia-related admissions.   
Approximately 1 year ago, the client developed a personalized manual technique that he 
uses frequently with great success. Briefly, the client removes the ventilation tubing from the 
lateral aspect of the tracheostomy hardware; he is able to maintain his airway for several minutes 
without direct ventilatory support. Following separation with the ventilation pump, the client 
seals the small opening on the tracheostomy apparatus with his thumb. Simultaneously, the 
caretaker connects a vacuum pump to the end of the tracheostomy port perpendicular to the 
anterior neck, which contains a small catheter that can advance into the central airways to suction 
out secretions. As the vacuum pump is inducing negative pressure in the airways, the client’s 
thumb-seal allows this negative pressure to build up inside of the airways. The client has 
performed this technique enough times such that he is able to feel an increasing degree of suction 
imposed on the thumb sealing the ventilation port. The client releases the thumb-seal at a self-
defined level of suction felt on his thumb, which forces a rapid elimination of the negative 
pressure gradient and seemingly augments a strong exsufflation as described in the problem 
description section of this report. As a result of this pressure change, secretions are believed to 
move proximally and eventually into the suctioning device, clearing the central airways after 
multiple cycles of the technique. He is able to perform this anywhere, provided he has the 
necessary assistance. The client claims he has had no pneumonia-related admissions since 
development of this technique. Despite the technique’s success, the client and his caretaker are 
not satisfied with the need for assembly deconstruction prior to technique performance.  
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Design Requirements for Project Specification  
 
There were fifteen design requirements that were used to develop QuickCough. These 
requirements and their descriptions can be seen in Table 1 below.  
 
Table 1: Design Requirements 
Requirement Purpose Numerical Value 
QuickCough cannot exceed the 
mean weight of provided ventilator 
attachments. 
Ensures that the device will not 
weigh down the tracheostomy port 
and ventilator tubing. 
Mean weight of 
ventilator 
attachment: 11.9 g 
QuickCough must be no larger than 
the largest ventilator adaptor 
provided by the client. 
Ensures that the device will not 
interfere with the tracheostomy port 
and ventilator tubing. 
Dimensions of 
largest ventilator 
adaptor: 8.5 cm x 
4 cm x 4.5 cm  
QuickCough must provide an 
airtight seal when activated.  
An airtight seal is essential to 
generating a negative pressure in 
the lungs to increase the efficacy of 
secretion expulsion. This was tested 
by submerging the device in water 
and blowing air through the device 
to see if any bubbles were 
generated. 
In a bubble test, 0 
bubbles must be 
generated 
QuickCough cannot decrease the 
tidal volume of the patient. 
The device is intended to be worn at 
all times and that would not be 
possible if it was impeding the flow 
of air to the client. 
Patient’s tidal 
volume should not 
be less than 207 
ml per inspiration 
(Dexter, 2018) 
QuickCough must be compatible 
with the tracheostomy port, 
ventilator tubing and ventilator 
attachments.  
For the device to be used properly, 
it must live in line with the 
ventilator tubing, attachments and 
tracheostomy port, which is 
measured by the outer diameter 
(OD) and inner diameter (ID) of the 
tubing. 
 
 
 
 
 
Outlet  
- OD 1.9 cm 
- ID 1.7 cm 
Intlet  
- OD 1.5 cm 
- ID 1.3 cm 
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QuickCough must be easily 
activated.  
The device is intended to be used 
by a caregiver or the patient 
themselves so it must not require 
much force to compress the button. 
It requires 12.9 N to hit a keystroke 
(Dennerlein, 2009) so this amount 
of force or less is acceptable for the 
user to expend when using the 
device. 
 
The force required 
to hit a keystroke: 
12.9 N 
QuickCough must be able to 
withstand a life cycle of 1 month.  
A greater life cycle would require 
fewer replacements for the client. 
Every three days, the client expels 
secretions 100 times. So, in a 30-
day month, the client will use the 
device about 1,000 times. 
Number of 
compressions 
required to 
simulate one 
month of use and 
wear: 1000 
compressions 
QuickCough must be able to 
withstand a shelf life of 2 years. 
A shelf life of 2 years allows for the 
device to be produced in bulk about 
once a year, instead of creating a 
new device each month. 
Required shelf 
life: 2 years 
QuickCough must generate a 
breathing waveform, as seen in 
other devices that occludes airway, 
when attached to a lung simulator. 
This waveform ensures that a 
proper seal is generated and that the 
device will not hurt the patient 
Visual inspection 
and analysis of 
data from testing 
with Ms. Volsko 
at Akron 
Children’s 
Hospital 
QuickCough must have a safety 
feature which prevents 
unintentional activation. 
Safety is always the highest priority 
and a failsafe must always be 
included in a device. 
N/A 
QuickCough must be made of a 
material which can withstand high 
temperatures for cleaning within a 
dishwasher. 
The device must be easily cleaned. 
The average maximum temperature 
a dishwasher reaches is 180 ℉ [36] 
Washing machine 
maximum 
temperature: 180 
℉ 
QuickCough must be made of a 
material which does not induce an 
immune response when in contact 
with the patient. 
As this device will always be in 
contact with the patient, it is 
important that the material in the 
device does not irritate the user.  
 
N/A 
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QuickCough must be made of a 
material which is disposable. 
Ensures that the device is non-
hazardous waste and can be 
disposed of in a trashcan. 
N/A 
QuickCough must be easily 
manufactured by 3D printing. 
Ensures low cost and ease of 
building. 
N/A 
QuickCough must allow the user to 
feel how much pressure is being 
applied when it is activated. 
Currently, the user is able to feel 
how much pressure is being 
generated on their thumb when they 
perform this technique. The client 
would like to keep this feature. 
N/A 
 
 
Test  
 
The device underwent 27 test cases, categorized in Table 2. Each evaluation method had 
qualitative or quantitative criteria for success. The device passed each test case described in 
Table 2 unless discussed below. The device failed 2 tests, had 6 acceptable failures (equivalent 
passes), and passed the remaining 19 tests. In depth descriptions and results of each test are 
found in the Appendix.  
Acceptable Failures 
The first acceptable failure is that the device is not entirely 3D printed. This is acceptable 
because the screws and tubing are easily acquired and assembled. Another acceptable failure is 
the size of the device, which does not exceed 2 centimeters past the criteria in any dimension. It 
is also acceptable that the silicone tubing failed in pushing the plunger back up in 5 seconds, as it 
was able to return to neutral position in 8 seconds. The device required more than 12.9 N to 
depress the plunger, but this result is an acceptable failure because the human factors test 
subjects were able to depress the plunger without undue burden and there was insufficient 
equipment to test this case. Similarly, the device acceptably failed shelf life and lifecycle testing 
due to inaccessibility of equipment.  
Failures  
The device failed the weight test case and is approximately 6 times the goal weight. The 
goal weight is the mean weight of provided ventilator equipment, 12 grams, while the device 
weighs approximately 70 grams. Another failure of the device is its inability to provide tactile or 
electronic pressure feedback. These items could be fixed in a second version of this product, but 
cannot be addressed at this time. 
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Table 2. Testing results (summarized into categories).  
 
Test Category Evaluations 
Marketing and 
Manufacturing 
The device comes with instructions or graphics on the device to ensure 
proper use, is not easily manufactured via 3D printing, is easy to replace, is 
easy to use, and is not difficult to train people to use 
Measurement The device is 1.4 times larger than the largest device attachment the 
customer provided us, is easy to transport, and weighs about 6 times more 
than the heaviest attachment. 
Material 
Analysis 
The device is biocompatible, is compatible with air, is compatible with 
water, can withstand machine washing in a dishwasher, is disposable after a 
certain period of use, does not contain any electrical components, and does 
not collect data. 
Occluding the 
airway 
The airway is instantaneously blocked when the user wishes to close the 
airway and there is a way to ensure that the device will never lock in the 
closed position. The silicone tubing takes 8 seconds to push the button back 
into a neutral position, more than 12.9 N is required to compress the button 
and plunger, and the user is not able to physically feel how much pressure is 
being applied. The device will create a pressure waveform, does not leak 
any air, does not restrict airflow, and is comfortable to use. 
Fit with 
attachments 
The device fits in line with the ventilation tube and with other ventilation 
tube adaptors 
Wear on the 
device 
We were unable to test if the device can withstand a 1 month of use or has a 
shelf life of 2 years.  
 
 
Business Aspects 
 
QuickCough’s similarity with the component for Haylard’s closed suction tracheostomy 
tube make it possible to run into patent laws for the design, which could pose an issue to sell this 
product commercially. However, if a patent lawyer was consulted with and the device was 
deemed fit for patentability the following plan would be implemented. QuickCough is specific 
for those who are able to have at-home care with a ventilator. The transition from the hospital to 
the home follows a strict protocol, with the fifth mentioning home equipment (HME) companies, 
“Provide HME company with a list of equipment and supplies” [37]. These HME companies 
would ultimately be the entities which would pay us. The goal would be to leverage a business to 
business approach, targeting the companies so we can reach the largest number of patients. 
QuickCough would be patented and the rights would be leased to the HME companies so that 
they will be the ones creating the physical product. Revenue would be made through the lease by 
per-unit sales royalties and twice a year the leasing contract would expire so that the royalties 
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can be adjusted for inflation and other economic variables. The profit will be maximized and 
overhead reduced since we eliminate the need for a distribution network by leasing the design. 
Additionally, marketing, advertising and promoting would be the responsibility of the lessee. 
After review of the initial business proposal outlined in a presentation on March 11th, 2019 and 
summarized in the paragraph above, the team has decided that no further updates/alterations are 
necessary.  
 
Final Implementation 
 
Our final design for the QuickCough mechanism is displayed in the expanded drawing 
below (Figure 3). The device consists of a lower housing (part 8), which is 3D printed, holds the 
silicone tubing (part 7) in place, and allows for ventilation tubing and other attachments to fit 
onto either end of the device. The upper housing (part 6) is also 3D printed and connects to the 
lower housing with four screws (parts 1). There is a slot through the middle of this upper 
housing, which allows for the plunger (part 5) to move vertically and compress the silicone 
tubing when a user depresses it. The cap (part 4) attaches to the plunger with a screw. This piece 
provides comfort for the user and ensures a firm grip on the device. The safety cage (parts 3) 
snugly fits around the neck of the plunger with the use of neodymium magnets (parts 2) to 
prevent the plunger from being compressed and closing the patient’s airway prematurely or 
permanently. The safety cage must be on the device at all times and should be removed before 
use. Detailed drawings of each assembly can be found in the Section E of the Appendix. 
 
 
Figure 3. Exploded view of the device. 1 - Self-tapping screws. 2 - Neodymium magnets with adhesive. 3- Safety cage. 4 - Top cap for plunger. 5 
- Plunger Body. 6 - Upper housing of main body assembly. 7 - Silicone tubing. 8 - Lower housing of main body assembly.  
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The device will remain attached to the patient’s tracheostomy port at all times, except 
when it needs disconnected for regular cleaning and maintenance. When a user wants to use this 
device, they will remove the safety cage from the plunger and compress the device for no longer 
than 16 seconds. When an appropriate level of negative pressure is achieved (this is to be 
determined by the client and their comfort level), the user will release the button and air from the 
ventilator will be reintroduced to the client’s lungs. After use, the safety cage must be reattached 
to the neck of the plunger. 
A description of airflow through the device can be found in the below block diagram 
(Figure 4). Air will begin at the ventilator and travel through the input of the device. If the client 
does not wish to expel secretions from their lungs, the safety guard will remain on the device, 
which will prevent the button and plunger from being compressed. The air will continue its 
journey through the silicone tubing (located in the housing), leave the device through the outlet, 
and eventually travel into the user’s lungs. Air can then be exhaled from the lungs by traveling in 
the opposite direction out of the device and back towards the ventilator. If the user wishes to 
expel secretions from the lungs, the user will remove the safety guard and compress the newly-
freed button. This button will depress the plunger and pinch the silicone tubing, creating a seal. 
At the same time, one end of the tracheostomy port will be hooked up to a pump, which is 
constantly running and trying to pull secretions from the lungs. The combination of this pump 
(which is removing air from the lungs) and the seal within the device (which prevents air from 
entering the lungs) creates a negative pressure in the lungs. This negative pressure is used to 
draw mucous in the lungs towards the bronchial tubes and eventually sucked out by the pump, 
simulating a cough. When an appropriate level of negative pressure is created (as defined by the 
patient), the button can be released so that air will re-enter the lungs. This process can then be 
repeated to expel more secretions, or the safety guard can be replaced and allow the user to 
breathe normally until the next time secretions must be expelled. 
 
Deliverables 
 
Year-long deliverables to both the professor and to the client are outlined in our 
Memorandum of Understanding (MOU). Deliverables to the advisor include the design history 
file, the NABC (Need, Approach, Benefits, and Competition) project sheet, project 
specifications, the initial drawings, meeting minutes, design verification document, test plan, 
decision matrix, video demonstration, and an executive summary. To the client, we will deliver 
intellectual property rights, the final prototype, Solidworks files and images, project 
specifications, and the design verification document. 
 
Scope of Work Excluded 
 
At the beginning of the semester, we established with the client that deliverables will 
consist of a complete design file and working prototype. The intention behind these items is that 
these documents will contain sufficient information for the client to manufacture these parts on 
their own. Over the course of the year, our scope expanded slightly to include instructions for 
how to use the device, but this is a very minor addition to the project.  
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Figure 4. Block diagram of airflow through the QuickCough device. Air starts at the ventilator, travels into the input of the device, and will travel 
through the device to the lungs if the safety guard is in act or will stop if the button is compressed and the silicone tubing is sealed.  
 
Performance Test Results  
 
From our testing at Akron Children’s Hospital with our mentor, Ms. Terry Volsko, we 
found that the QuickCough device was able to generate a viable waveform on the lung simulator 
that was sufficient to seal the airway shut and create a negative pressure in the user’s lungs. 
Furthermore, upon releasing of the plunger to allow air to enter the lungs again, the plunger 
quickly returned to a neutral position to restore airflow back to the levels that it was at before 
occlusion (Figure 5). While these two results were anticipated before testing, it was not expected 
that the device would weigh almost 6 times greater than the average attachment. Previous 
estimates for the weight of the device had only included the 3D printed plastic housing. When 
we discovered that the housing itself could not create a sufficient seal, the silicone tubing, two-
part housing that is attached with a total of five screws, and the safety cage were added to the 
design. Each component is required to carry out the complete functions of the device while still 
remaining safe for the client. As expanded upon in Section XIII Future Work, the weight of the 
device could be reduced in future versions of the device. 
Another customer requirement that we failed to meet was creating a way for the user to 
verify that the device created an airtight seal. The current technique that the client uses for this 
process allows for the user to feel the pressure that is generated in the lungs on their thumb. 
While it is not explicitly necessary for the function of the device, by assessing the pressure 
generated in the lungs the user is able to verify that the device is functioning normally, and that 
maximum mucous secretion is achieved.  
It was also expected that the entire device would be 3D-printed in order to allow quick 
and cheap manufacturing for the user with minimum processing. With the addition of screws and 
silicone tubing, the device is no longer entirely 3D printed. Greater than 80% of the device is 3D 
printed but requires post-processing of the device and some fine maneuvering is required to clear 
out all of the extra plastic material. The addition of the silicone tubing ensures that an airtight 
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seal is created every time but attaching the tubing into the housing is neither quick nor easy - it 
takes both timing and the right touch in order to securely attach the tubing within the lower 
housing. The addition of self-tapping screws into the device takes a little bit more time to 
assemble the completed device but ensures that the upper and lower housings are securely 
attached and reduces the likelihood that the silicone tubing will disconnect from the inner ports 
of the housing.  
All other test cases succeeded, including the compatibility of the device with the patient 
and environment, the creation of an airtight seal, and the ability of the device to connect to the 
ventilation tubing and other attachments.  
Future design considerations to alleviate the issues cited above include decreasing the 
overall weight of the device by removing excess material. Additionally, instead of splitting the 
housing into two parts horizontally, the device could be split vertically. A vertical split would 
allow for easier 3D printing as the top cap would no longer be printed in two parts and it would 
become easier to attach the tubing within the housing.  
 
 
Figure 5. Airway pressure during the occlusion of two breath cycles. Notably, from seconds 4-8 a waveform is maintained during occlusion, 
similar to analogous devices. 
 
 
Progress 
 
While the goal of the team was to implement each and every specification, some 
specifications were not reasonable to impose on the product. For example, upon development of 
the initial prototype, it was discovered that an entirely 3D printed mechanism would not be 
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suitable for use as intended. Upon the next iteration, a silicone tube was introduced to the design 
to accomplish a relatively easy activation, airtight seal and minimal impedance of airflow. 
Another specification that was not implemented was that QuickCough be no larger than the 
largest ventilator adaptor provided by the client (8.5 cm x 4 cm x 4.5 cm). This specification was 
not implemented because the device simply cannot be decreased in volume due to the design. In 
future iterations of the QuickCough, the team could consider ways to shrink the size of the 
device. A third specification that was not implemented was that when the user activated the 
device by pressing the button, they would be able to feel by touch or visual aid how much 
pressure is being exerted on the lungs. This aspect was brought up by the client during the design 
development and due to time constraints it was not feasible to implement in the current design. 
However, further iterations of QuickCough could potentially satisfy this specification. The last 
two specifications that were not implemented into the design were regarding the wear on the 
device. The life cycle specification was unable to be implemented due to the lack of availability 
of highly accelerated life testing equipment, while the shelf life specification could not be 
implemented due to time constraints for testing. 
 
Individual Contributions 
 
Russell was the primary contact with our mentor, Ms. Terry Volsko at Akron Children’s 
Hospital. He completed substantial background and market research for the device and created 
the work distribution sheet. He coordinated test plans and developed a basic understanding of the 
testing model to evaluate QuickCough’s performance once data had been collected.  
Mariah helped with the data collection with Ms. Volsko at Akron Children’s for the 
device, interpreted the data gathered from the testing machines, helped with designing the 
prototypes through iterations, developed and maintained the Gantt chart for the entire product 
development cycle, developed the decision matrix selecting a prototype, created the bill of 
materials of the device, and worked with an advisor to create with a safety feature for the device.  
Sydney met with the customer for the initial meeting in order to develop the customer 
requirements document, assisted in designing the newest iteration of the device, completed our 
market analysis, documented and organized a majority of the DHF, created the specification 
document, ordered the silicone tubing, and organized and maintained the team google drive. 
Madison served as the primary contact point with the client, created the design 
verification document, recorded meeting minutes during all team meetings, developed the MOU 
and received sign-off from the client, created the block diagram of how the device’s function, 
assisted with testing at Akron Children’s, and met with the client several times. 
Sean did the majority of the CAD drawings for the device throughout all iterations. He 
was the primary contact with Steve Paterson for 3D printing the device, investigated 
manufactured valves to improve the device design, met with Dr. Willits to come up with the 
silicone tubing addition, and ordered the magnets and tubing for the device. 
 
Financial Considerations 
 
Overall, Cough-Start costs about $36 to manufacture (Table A), includeing the cost of 
the 3D print, self-tapping screws, magnets, and tubing. Looking at the other devices mentioned 
above, Cough-Start is actually the second cheapest (Table B). However, the majority of the price 
for Cough-Start comes from the price of the magnets. Nonetheless, the time required to make the 
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device has the majority of the time spent in the 3D printing process. The actual assembly of the 
device is relatively quick. This is the case because the idea for the device is that it would be 
possible for the end-user to manufacturer so the price for manufacturing would not be an issue 
allowing the product to stay cheaper.  
 
Table A. Pricing for the different components of the device. Prices listed here are the pricing 
needed to make exactly one of the device.  
Part Amount required Price per part 
Total Cost of 
Parts 
Overall 3D print cost in 
Raptor PLA 
0.15 lb $32.99/lb $4.95 
No. 4 self-tapping screws 5 $9.65/50 screws $0.97 
Silicone tubing 2.5 in $5.60/24 in $0.58 
Magnets 4 $7.26/magnet $29.04 
 
Table B. Condensed product comparison table between the QuickCough device, mechanical 
insufflation-exsufflation (MI-E), Bag-Valve Mask (BVM), and Intermittent Positive Pressure 
Breathing (IPPB) used in proximal cough assistance. Popular producers are listed in the 
Company column. Four important customer needs are used for the comparison, including: the 
manual nature of the device, comfort during use, cost, and portability.  
Product Company Manual Comfortable Expensive Portable 
Quick-Cough — YES YES NO YES 
MI-E 
Respironics, Hill-Rom, 
Phillips, Emerson 
NO NO YES NO 
BVM 
Medline Industries, Ambu, 
Moore– 
Medical, MCR Medical 
YES NO NO YES 
IPPB 
Axcent Medical, Air 
Liquide Healthcare, 
InterSurgical, Hill-Rom 
NO NO YES NO 
 
Summary Feasibility Discussion 
 
The need identified at the beginning of the effort was to convert the client’s technique for 
increased efficiency of secretion expulsion into a physical product which could live in line with 
his ventilator tubing and port. The technique that was used by the client consisted of him 
detaching himself from the ventilator and covering the ventilator port with his thumb while the 
suctioning assembly was in use. The QuickCough device replicates the thumb of the client by 
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completely sealing airflow into the tracheostomy port and generating a negative pressure within 
the lungs. Additionally, QuickCough can be attached to the ventilator port, tubing and specific 
attachments (humidifier, inhaler, etc.). This alone proves that the need identified at the beginning 
of the effort was satisfied. However, it is important to note that certain design specifications were 
unable to be met and therefore requires further iterations of QuickCough to be developed. 
Currently, QuickCough is considered a prototype for a variety of reasons. The first being 
that QuickCough demonstrates multiple functional aspects of the design instead of just one 
(therefore differentiating it from a proof-of-concept model) [38]. A second reason is that 
additional testing must be completed to ensure that there are no errors present in the design so 
that final product construction can be competed [38]. Also, certain product specifications were 
unmet and are important to satisfy in order for QuickCough to enter the market and be put on 
patients. 
 
Future Work 
 
This device has room for development in future iterations, particularly in cases of mass 
production and increased budget. One customer requirement left unfilled was the request for the 
device to “allow the user to know how much pressure is being applied when it is activated.” The 
current method of achieving this action is the inclusion of an open hole in the device. The patient 
or caregiver can place their thumb over this hole to feel the pressure change. Because the team 
wanted a continuous, closed, and quasi-permanent pathway from the ventilator to the patient, the 
device has no open hole. However, in a high tech, high budget iteration, a pressure sensor and 
user interface could also achieve this result. While expensive, the addition of the pressure sensor 
could introduce a momentous safety feature: the ability to detect and alert others if the patient is 
no longer receiving ventilation. This feature would be critical for patients who suffer from 
neuromuscular disorders, who may helpless to correct an airway blockage. A pressure sensor and 
user interface with an accompanying alarm feature would help give caregivers more time to 
correct blockages, saving patient lives. Further, this feature would help caregivers optimize 
pressure differences in the secretion expulsion process while maintaining patient comfort and 
cleanliness.  
This device could also be improved by making it smaller and, with the addition of a 
pressure sensor, could improve the patient’s comfort as the device is always connected to the 
ventilation tubing and resting near the patient’s neck and head. Future work should also go into 
researching a better closure solution for the safety cage. Currently, magnets were used to close 
the safety cage. These magnets were costly, accounting for 85% of the product cost, which was 
acceptable with the current device, as this safety feature was critical to the success of the device. 
However, the closure mechanism can be optimized for cost. Finally, future work could include 
decreasing the amount of force that is required to close the airway. While we did not find an 
exact value for the force required to compress the button, it seems to be larger than our goal of 
12.9 N. 
 
Discussion, Conclusions, Lessons Learned, and Recommendations  
 
The device has gone through several major design revisions from when it was first 
drafted. Initially the device started out as a component similar to what was already a part of the 
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entire suctioning assembly. However, with time, many issues were found that needed to be 
solved. These issues were all essentially solved by introducing a silicone tube. However, to 
accommodate for the tube, the device had to become larger and became less like the part already 
present on the assembly. By using this version, it was possible to gather test data to show that the 
device was capable of producing the necessary seal. However, the device was not without issues. 
The device did not have an intrinsic safety precaution built into the main body assembly, so a 
safety cage had to be developed, detached from the rest of the device. This addition increased the 
overall bulk of the entire device. It would be recommended for future iterations of the device to 
avoid having this extra bulk on the top and to instead find a way to incorporate it into the the 
design of the main body.  
One of the biggest lessons from this project was the importance of deadlines and how, 
even with impending deadlines, design iterations can still be created. If we were to do this 
project again or create a second version of the QuickCough device, we would work to complete 
brainstorming by October, have an initial prototype before winter break, and begin creating 
iterations of the prototype and testing as soon as classes began again in January. 
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Appendices 
 
A. Design Verification Matrix 
 
Test 
Case 
ID 
Test Case Description Actual Output Pass/Fail 
1 
device comes with 
instructions or graphics 
on the device to ensure 
proper use 
Instructions are provided with the 
device 
Graphical instruction document Pass 
2 
device is easily 
manufactured via 3D 
printing 
the device is 3D printed 
The device is not entirely 3D 
printed (as tubing and screws are 
present) and needs to be 
processed by an expert 
Acceptable 
Failure 
3 
the device is easy to 
replace 
The device takes less than 24 hours 
to 3D print and costs less than $30 
to replace 
The device takes approximately 
24 hours to print and costs 
approximately $26 to print 
Pass 
4 
it is easy to use and not 
difficult to train people 
to use 
It takes a new user less than 60 
seconds to comprehend how the 
device works and how it should be 
used 
2 human factors tests proved 
healthcare providers could 
understand in 60 seconds or less 
Pass 
     
Measurement    
5 device is small 
Device is no larger than the largest 
attachment that our client provided 
us with: 8.5 cm x 4 cm x 4.5 cm 
The device has a length of 9.79 
cm, width of 4.10 cm, and height 
of 5.26 cm 
Acceptable 
Failure 
 
6 
device is easy to 
transport 
the device can easily fit within a 
coat pocket (10 cm x 8 cm) 
The device fits within a coat 
pocket that is 10 cm x 8 cm 
Pass 
7 device is light 
device weighs less than 11.91217 g 
(the mean weight of provided 
ventilator equipment - 
tracheostomy port & ventilator 
attachments) 
Device weighs approximately 70 
grams 
Fail 
     
Material Analysis    
8 device is biocompatible 
Raptor, silicone, and the screws do 
not cause irritation to skin 
All are biocompatible (Sydney 
has research articles) 
Pass 
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9 
device is compatible 
with air 
the casing and tubing remains 
completely intact and functional 
when it comes into contact with air 
the device maintains full 
functionality when exposed to air 
Pass 
10 
device is compatible 
with water 
the casing and tubing remains 
completely intact and functional 
when it comes into contact with 
water 
the device maintains full 
functionality when exposed to 
water 
Pass 
11 
device can withstand 
machine washing in a 
dishwasher 
the casing and tubing remains 
completely intact and functional 
after going through a dishwasher 
cycle. The device will be seperated 
in the dishwasher, top rack, with 
dishwashing detergent 
Device maintains functionality 
after dishwashing 
Pass 
12 
device is disposable after 
a certain period of use 
The device is non-hazardous waste 
and can be disposed in a trash can 
Non hazardous waste Pass 
13 
there are no electrical 
components to this 
device 
there are no electrical components 
on the device 
no electrical components are in 
the device 
Pass 
14 
data is not collected 
from this device 
data is not collected from this 
device 
no data collected by device Pass 
     
Occluding the airway    
15 
airway is 
instantaneously blocked 
when the user wishes to 
close the airway 
It should take < 1 second for a 
complete seal to be reached after 
activating the device. From the 
time the button was compressed to 
the time that the airflow became 
stable again, occluded flow 
waveform formed is < 1 second 
difference 
The device is able to block 
airflow in 0.1 seconds 
Pass 
16 
device will create a 
pressure waveform 
When attached to the artificial 
lungs, a smaller pressure waveform 
is created with the occluded airway 
than when the device is open and 
the airway is not occluded. The 
pressure waveform is similar to 
that found for similar devices 
The device is able to mimic a 
pressure waveform seen in 
Figure 1, "Airway Pressure 
During Device Occlusion." 
Pass 
17 
there is a way to ensure 
that the device will 
never lock in the closed 
position 
The device will never be in a 
locked position unless a person is 
actively and intentionally pushing 
on it 
Safety cage prevents lock in 
closed position when not in use 
Pass 
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18 
silicone is strong enough 
to push button back up 
when compressed and released, it 
will take the button less than 5 
seconds to completely return to 
resting position 
Device took 8 seconds to return 
to neutral position 
Acceptable 
failure 
19 
not much force is needed 
to press down on the 
button 
the amount of force required to 
compress the button should be less 
than 12.9 N (the force required to 
press a key on a computer 
keyboard) 
Equipment for testing 
unavailable. Anecdotal human 
factors testing indicated the 
device required slightly too much 
force to close, but did not provide 
undue burden 
Acceptable 
failure 
20 
to press down on the 
button, there is a thumb 
indent for the comfort of 
the user 
a thumb indent is present to ensure 
comfort for the user when they 
press down on it 
a thumb indent is present Pass 
21 
user must be able to feel 
how much pressure is 
being applied when the 
button is pressed down 
when the user compresses the 
button, they are able to feel by 
touch or visual aid how much 
pressure is being exerted on the 
lungs 
No tactile or electronic pressure 
feedback 
Fail 
22 
the device does not leak 
any air 
The device is place with one end 
underwater and a tube attached to 
the end sticking out to the water. 
When air is blown into the device 
and the button is compressed, no 
bubbles are generated 
No bubbles are generated, which 
means that no air passes through 
the device 
Pass 
23 
air flow is not restricted 
through the device 
the breath that passes through the 
device is not constricted by the 
device. The non-occluded breaths 
from our measurements match 
normal breath patterns that one 
would expect from a child with a 
neuromuscular disorder 
Airflow is maintained when 
device is inactive. This is 
validated during the first and last 
3 breath cycles in Figure 1 of the 
Final Report, "Airflow Pressure 
During Device Occlusion." 
Pass 
     
Fit with attachments    
24 
the device fits in line 
with the ventilation tube 
The device connects snuggly with 
the ventilation tubing and will not 
easily disconnect so that the user 
can keep the device in line with the 
ventilation tubing all day 
The device fits in line with the 
tracheostomy tubing 
Pass 
25 
device will fit with other 
ventilation tube adaptors 
The device will fit in line with the 
ventilation system and attachments 
can fit on either side of the device 
Are there standards for this? 
The device attaches to other 
tracheostomy attachments on the 
smaller port only 
Pass 
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Wear on the device    
26 
device can withstand a 
life cycle of 1 month 
before needing to be 
replaced 
The device will perform at the 
same level as it had before testing 
after a simulated month's use of 
wear (1000 compressions) 
 
Acceptable 
Failure 
27 
shelf life of the device is 
2 years 
The device, when left unused, will 
still work at full capacity after two 
years 
Equipment for highly accelerated 
life testing unavailable. 
Acceptable 
Failure 
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B. SolidWorks Figures 
 
 
Exploded view of device with all component 
 
 
 
 
Top part of housing assembly 
 
 
 
Bottom part of housing assembly 
 
Assembled view of device 
 
 
 
 
Top cap of plunger component 
 
 
 
 
Plunger component 
 
 
 
One half of the safety cage
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C. Graphical Instruction 
 
 
QUICKCOUGH 
Cough assist permanently inline with ventilator for use at home and on 
the go.  
ADVISORIES 
Do not detach patient ventilator. Ensure safety cage removal before use 
and replacement upon completion. For sanitation, dishwash at highest 
temperature setting with antibacterial detergent. Sanitize at every 
tracheostomy port change, every 3-4 days. Replace device every 2-3 
weeks. Shelf life: 2 years. 
 
DIRECTIONS 
1. Maintain device in neutral 
position inline with 
ventilator (Figure 1) 
2. Insert suctioning equipment 
into patient tracheostomy 
port 
3. Depress plunger to block 
airflow completely  
Maintain force no longer 
than 15 seconds 
 (Figure 2). 
4. Suction secretions 
5. Elevate plunger to neutral 
position. 
6. Remove suctioning 
equipment. 
 
Figure 1. Neutral position 
  
 
Figure 2. Activated position 
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D. MATLAB data extraction code 
 
A=importdata('data2.rwa'); 
Time_import=A.data(:,1); 
T_start=find(Time_import==74); 
T_end=find(Time_import==85); 
Time=Time_import(T_start:T_end,:); 
Time_shift=linspace(0,12,length(Time)); 
AirwayPressure=A.data(T_start:T_end,2); 
plot(Time_shift,AirwayPressure) 
title('Airway Pressure During Device Occlusion') 
xlabel('Time (s)') 
ylabel('Pressure (cmH20)') 
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E. Drawings of the Individual 3D printed parts 
All dimensions shown are in millimeters 
 
Top part of main assembly 
 
 
Bottom part of main assembly 
 
 
Top part of plunger component 
 
 
 
 
 
Bottom part of plunger component 
 
 
Safety Cage 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
